The Palmetto Peptides Guide to the Research Peptide Selank
The Palmetto Peptides Guide to the Research Peptide Selank
Meta Title: Selank research peptide: The Complete Laboratory Guide | Palmetto Peptides
Meta Description: The definitive research guide to Selank — covering molecular structure, preclinical findings, mechanisms of action, synthesis, storage, and sourcing standards for laboratory researchers.
Last Updated: 2025
Author: Palmetto Peptides Research Team
Research Use Only Disclaimer: Selank is sold exclusively for in vitro laboratory and preclinical research purposes. It is not approved by the FDA or any other regulatory authority for human or veterinary use. All information in this guide is intended for licensed researchers and scientific professionals. Nothing on this page constitutes medical advice.
What Is Selank Research Peptide? A Direct Answer for Researchers
Selank is a synthetic heptapeptide research compound with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed as an analog of the naturally occurring immunomodulatory peptide tuftsin at the Institute of Molecular Genetics of the Russian Academy of Sciences. In preclinical animal model research, Selank has been studied primarily for its effects on anxiety-related behavior, serotonin metabolism, BDNF expression, and GABA-A receptor interactions.
It is not approved for human or veterinary use. It is available in the United States strictly for research purposes.
That is the short version. The rest of this guide covers everything a laboratory researcher needs to know — from the molecular structure and synthesis process to preclinical findings, storage best practices, and how to evaluate suppliers.
Background: Where Selank Comes From and Why It Matters
Understanding a research peptide's origin is foundational, not optional. The development history of Selank tells you why it was built the way it was, what it was designed to do, and why the preclinical literature looks the way it does.
The Tuftsin Connection
Selank's design begins with tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced primarily in the spleen and first described by Victor Najjar and colleagues in the late 1960s. Tuftsin functions as a natural immunostimulant, activating phagocytic cells including macrophages and monocytes. Researchers found it interesting but impractical as a research tool because it degrades rapidly in biological systems.
The scientists who developed Selank set out to create a more stable analog. They kept tuftsin's four-residue sequence intact and added a synthetic C-terminal extension — Pro-Gly-Pro — to create the full seven-residue Selank sequence. That extension was deliberate: proline residues resist many common peptidases, giving Selank improved metabolic stability while expanding its research potential beyond classical immunology.
What followed was a gradual pivot in research focus. As preclinical animal model data accumulated through the 1980s and 1990s, researchers documented behavioral and neurochemical effects that were more consistent with anxiolytic and cognitive activity than classic immune modulation. Selank's research trajectory shifted toward neuroscience, and that is where the majority of published literature sits today.
For deeper context on the historical development, see our supporting article: History and Development of Selank Research Peptide: From Tuftsin Analog to Modern Lab Research Tool.
Molecular Structure: What the Sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro Actually Means
Selank is a heptapeptide — a chain of seven amino acids. Its full sequence is:
Threonine — Lysine — Proline — Arginine — Proline — Glycine — Proline
Here is what each part of that sequence contributes:
| Position | Residue | Key Property |
|---|---|---|
| 1 | Threonine (Thr) | Polar; contributes to hydrogen bonding and receptor recognition |
| 2 | Lysine (Lys) | Positively charged; critical for bioactivity in tuftsin-derived peptides |
| 3 | Proline (Pro) | Rigid cyclic structure; constrains backbone conformation |
| 4 | Arginine (Arg) | Strongly positively charged; participates in electrostatic interactions |
| 5 | Proline (Pro) | Part of synthetic C-terminal extension; improves stability |
| 6 | Glycine (Gly) | Smallest residue; provides conformational flexibility as a linker |
| 7 | Proline (Pro) | C-terminal proline; blocks exopeptidase degradation |
Molecular formula: C33H57N9O9
Molecular weight: Approximately 751.87 g/mol
CAS number: 129954-34-3
Appearance: White to off-white lyophilized powder
The three proline residues are the structural signature of Selank. Two of them (positions 5 and 7) are part of the engineered C-terminal Pro-Gly-Pro extension that distinguishes Selank from its tuftsin parent. This extension serves as a metabolic shield — proline's cyclic structure creates steric bulk that many peptidases cannot efficiently cleave, extending the compound's half-life in biological media compared to tuftsin alone.
For a complete breakdown of Selank's structural chemistry, see: Molecular Structure and Sequence of Selank Research Peptide: Key Chemical Properties for Lab Scientists.
How Selank Is Synthesized for Research Use
Research-grade Selank is produced using solid-phase peptide synthesis (SPPS) — specifically Fmoc chemistry, the industry standard for this class of compound.
In plain terms: the peptide is built one amino acid at a time, anchored to a solid resin bead, using a tightly controlled chemical assembly process. Once the full seven-residue chain is assembled, it is cleaved from the resin, purified by high-performance liquid chromatography (HPLC), and lyophilized into a stable powder.
Selank's synthesis has specific challenges worth noting. Three proline residues require careful coupling conditions — proline's ring structure makes bond formation slower and less efficient than for other amino acids. Poor coupling at proline positions leads to deletion sequences (chains missing a residue) that are difficult to remove and can confound assay results if present at meaningful concentrations.
This is why purity documentation is not a formality. A Selank vial without HPLC purity data and mass spectrometry identity confirmation has not been fully verified. Researchers should accept nothing less than greater than 98% HPLC purity with a full COA for serious preclinical work.
More on what to look for in a COA: Quality Control and Purity Testing Standards for Selank Research Peptides.
More on the synthesis process: Synthesis and Manufacturing of High-Purity Selank Research Peptide for Laboratory Use.
Preclinical Research: What Animal Model Studies Have Shown
The published preclinical record on Selank is substantial for a research peptide, spanning multiple research domains and coming primarily from Russian academic institutions over a period of several decades. Here is a summary of the key findings by domain.
Anxiety-Related Behavioral Models
This is the most consistently replicated finding in the Selank literature. Rodent studies using the elevated plus maze, conflict behavior tests, and open field paradigms have shown:
- Increased time in anxiogenic zones (open arms of the elevated plus maze) in Selank-treated animals
- No significant change in total locomotor activity at anxiolytic doses — meaning the behavioral changes are not simply sedation artifacts
- Consistent findings across multiple rodent models and research groups
This convergence across different paradigms gives the behavioral data more weight than any single study could provide on its own.
Serotonin and Monoamine System Effects
Neurochemical studies have documented altered serotonin (5-HT) turnover — measured by changes in the 5-HIAA/5-HT ratio — in rodent hippocampal and frontal cortex tissue following Selank administration. These brain regions are central to anxiety regulation and cognitive processing. The serotonin findings provide a neurochemical correlate to the behavioral anxiety data, suggesting mechanistic engagement with the serotonergic system rather than a purely behavioral artifact.
BDNF Expression
Gene expression studies by Kolomin and colleagues documented upregulation of BDNF (brain-derived neurotrophic factor) mRNA in rodent hippocampal tissue following Selank administration. BDNF is one of the most studied molecules in neuroscience — it supports neuronal survival, promotes synaptic plasticity, and plays key roles in learning and memory models. Its upregulation is consistently associated with positive adaptive outcomes in a wide range of experimental contexts.
Immunomodulatory Activity
Consistent with Selank's origins as a tuftsin analog, preclinical studies have also documented effects on immune parameters — including modulation of interleukin expression and lymphocyte activity in stress-combined immune challenge models. This neuroimmune dimension of Selank's activity profile makes it relevant to a broader range of research questions beyond pure neuroscience.
Broad Gene Expression Profiling
Comprehensive transcriptomic studies in rodent hippocampal tissue revealed that Selank administration produces changes across dozens of genes — including GABA receptor subunit genes, synaptic vesicle proteins, immediate early genes, and neuroprotective response elements. This breadth of gene expression activity suggests Selank's effects in neural tissue involve more than a single receptor interaction.
For a detailed review of preclinical study methodology and findings: Preclinical Research Findings on Selank Research Peptide in Animal Models.
Mechanisms of Action: How Selank Interacts with Biological Systems
Selank is not a single-target compound. The preclinical evidence points to several intersecting mechanisms that appear to operate simultaneously. Here is what has been documented.
GABA-A Receptor Interaction (Benzodiazepine Site)
The most precisely characterized molecular interaction involves the GABA-A receptor complex — the primary inhibitory receptor in the vertebrate central nervous system. Grigor'ev and colleagues (2006) published direct evidence showing Selank interacts with the benzodiazepine binding site of this receptor, acting as a positive allosteric modulator of GABA's effects.
To put this in accessible terms: the GABA-A receptor has multiple binding sites. The main site is where GABA (the brain's primary "calm down" signal) binds. There is a secondary site — the benzodiazepine site — where modulators can bind and amplify or reduce GABA's effect without activating the receptor independently. Selank appears to interact at this secondary site, augmenting inhibitory signaling when GABA is present.
This provides a mechanistic basis for the anxiolytic-like behavioral effects seen in animal models.
Enkephalin-Degrading Enzyme Inhibition
Enkephalins are endogenous opioid peptides that modulate pain and mood. They are rapidly cleared from the synapse by two enzymes: enkephalinase (NEP) and aminopeptidase N (APN). Preclinical data suggests Selank may inhibit both enzymes to varying degrees, prolonging the activity of natural enkephalins in the synapse. This is consistent with some of the stress-response behavioral outcomes observed in rodent models.
Serotonin System Modulation
Altered serotonin turnover in discrete brain regions has been documented repeatedly. The precise upstream mechanism — whether Selank acts directly on serotonin receptors, affects the reuptake transporter, or produces these changes through downstream consequences of its GABAergic or enkephalinergic activity — is not yet fully resolved. This represents an open research question.
BDNF Upregulation and Neurotrophic Signaling
Selank's documented BDNF upregulation in hippocampal tissue engages the TrkB receptor signaling cascade, which activates downstream pathways including MAPK/ERK and PI3K/Akt — both extensively studied in synaptic plasticity and neuronal survival research. The BDNF-TrkB interaction makes Selank relevant to neurotrophic factor research even if BDNF upregulation is a downstream consequence of primary mechanisms rather than a direct interaction.
For a full mechanistic deep-dive: Mechanisms of Action of Selank Research Peptide in Neuroscience and Gene Expression Studies.
Selank vs. Semax: Knowing Which Peptide Fits Your Research Question
Selank and Semax are frequently compared because they share structural similarities — both are heptapeptides with the Pro-Gly-Pro C-terminal extension — but their research profiles are meaningfully distinct.
| Feature | Selank | Semax |
|---|---|---|
| N-terminal origin | Tuftsin (Thr-Lys-Pro-Arg) | ACTH(4-7) (Met-Glu-His-Phe) |
| Primary preclinical focus | Anxiety models, serotonin, GABA | Cognitive/memory models, BDNF, neuroprotection |
| Documented receptor target | GABA-A (benzodiazepine site) | Melanocortin receptors (MC4R) |
| BDNF upregulation | Yes (documented) | Yes (more pronounced, more replicated) |
| Neuroimmune activity | Strong (tuftsin heritage) | Less pronounced |
The practical guidance: if your research question centers on anxiety-related behavioral models, GABA-A receptor pharmacology, neuroimmune interactions, or serotonin system studies, Selank is the better-supported choice. If your question centers on cognition, memory, neuroprotection, or BDNF-driven neurotrophic signaling, Semax has the stronger published precedent.
Both Selank and Semax are available at Palmetto Peptides with full COA documentation.
For a thorough side-by-side comparison: Selank Research Peptide vs Semax Research Peptide: Key Differences for Neuroscience Lab Studies.
Delivery and Formulation in Research Settings
Most published Selank preclinical studies use subcutaneous or intraperitoneal injection as the delivery route in rodent models. Intranasal delivery has also been studied, reflecting Selank's potential relevance to central nervous system research — the nasal cavity provides a potential pathway to CNS targets via olfactory and trigeminal nerve routes, bypassing some of the blood-brain barrier's filtering effects.
Researchers designing intranasal studies should be aware that rodent nasal anatomy differs significantly from other species — rodents have proportionally much more olfactory epithelium relative to total nasal mucosa, meaning delivery efficiency in rodent models may not translate proportionally to other experimental systems.
For a full breakdown of intranasal formulations and delivery considerations: Selank Research Peptide Nasal Spray Formulations: Applications in Controlled Research Settings.
Storage and Reconstitution: Protecting Your Research Investment
Improper handling is one of the most preventable sources of data quality problems in peptide research. Here are the key rules.
Lyophilized Selank Storage
- Store at -20°C for short-term use (up to 3 months)
- Store at -80°C for long-term storage (up to 24+ months)
- Keep vials sealed and dry until ready to use
- Allow sealed vials to reach room temperature before opening — this prevents condensation on the peptide when cold material meets warm, humid lab air
Reconstitution Protocol
- Allow vial to equilibrate to room temperature (15 to 30 minutes, sealed)
- Add sterile water or bacteriostatic water to achieve target concentration (1 mg/mL is standard)
- Swirl gently until dissolved — do not vortex
- Inspect for clarity; any cloudiness warrants investigation before use
- Aliquot immediately into single-use volumes and freeze
Freeze-Thaw Management
Never refreeze thawed aliquots. Each freeze-thaw cycle promotes peptide aggregation and degrades solution quality. Preparing single-use aliquots at reconstitution is the correct approach.
Reconstituted Selank stability:
| Storage Temperature | Estimated Usable Lifespan |
|---|---|
| +4°C (refrigerator) | Up to 7 days |
| -20°C (freezer) | Up to 30 days |
| -80°C (ultra-low freezer) | Up to 90 days |
For a complete handling protocol with step-by-step reconstitution guidance: Best Practices for Storage, Stability, and Reconstitution of Selank Research Peptide in the Lab.
Quality Control: What Research-Grade Selank Documentation Must Include
Researchers routinely accept COA documentation without examining it critically. That is a mistake. Here is what should be in a complete Selank COA and what each element tells you:
HPLC purity (%): The percentage of total chromatographic peak area attributable to the target peptide. Must be greater than 98% for research-grade material. The chromatogram trace itself — not just the number — should be included.
Mass spectrometry (MS) confirmation: Verifies molecular weight matching the expected ~751.87 Da for Selank. This is the sequence identity check. HPLC purity without MS data means you know the purity of the dominant compound but not whether it is actually Selank.
Net peptide content (%): The percentage of total vial weight that is actually peptide — as distinct from residual water, TFA counterions from HPLC purification, and other non-peptide material. A vial labeled 5 mg typically contains 3.5 to 4.5 mg of actual peptide. If you ignore this, your concentration calculations will be off.
Residual solvents: Trifluoroacetic acid (TFA) and acetonitrile (ACN) are the primary solvents used in HPLC purification. TFA is not biologically inert. Levels must be stated.
Lot number: Traceability from vial to specific synthesis batch.
A COA that does not contain all of these elements is not a complete quality document. Palmetto Peptides provides full COA documentation — including HPLC trace and mass spec data — with every lot.
How to Source High-Purity Selank for Your Laboratory
The research peptide market includes suppliers with genuinely robust quality infrastructure and suppliers who generate documentation without the underlying science. Distinguishing them before you order matters.
The Key Questions to Ask Any Supplier
- Can you provide a lot-specific COA before I order?
- Does the COA include the HPLC chromatogram trace, not just the purity percentage?
- What is the observed mass from MS, and does it match the theoretical 751.87 Da for Selank?
- What is the net peptide content?
- What are the residual TFA and ACN levels?
Legitimate suppliers answer all of these readily. Those who cannot or will not are telling you something important about their quality infrastructure.
Price and Quality
Research-grade Selank has a genuine cost structure — SPPS reagents, multiple HPLC purification runs, analytical testing, lyophilization, cold-chain handling, and documentation systems all contribute. A price substantially below market almost always reflects compromise somewhere in that chain. The most common cost-cutting points are reduced purification (lower purity accepted) and incomplete analytical testing (no MS, no net peptide content).
The cost of a wasted experiment exceeds the cost of any price difference.
For a complete buyer's guide: How to Buy High-Purity Selank Research Peptide Online: A Guide for Research Laboratories.
Selank in the Context of Neuropeptide Research
Selank occupies an interesting position in the broader neuropeptide research landscape. It is one of a relatively small number of research peptides with:
- A documented institutional development history spanning decades
- A verifiable research lineage (Russian Academy of Sciences, Zakusov Institute)
- Published preclinical data across multiple research domains (behavioral, neurochemical, transcriptomic, immunological)
- A known molecular mechanism with direct experimental evidence (GABA-A benzodiazepine site)
Many synthetic research peptides have limited published literature and unclear origins. Selank enters the lab with a meaningful scientific foundation — which is practically valuable for researchers designing studies, writing protocols, and situating their findings in the published record.
It also presents genuinely unresolved research questions. The full mechanism of action is not completely characterized. The relative contributions of GABA-A modulation, enkephalinase inhibition, and serotonergic effects to observed behavioral outcomes have not been definitively separated. The downstream drivers of broad transcriptional changes in hippocampal tissue are not fully understood.
These open questions are not weaknesses — they are the research opportunities.
Summary: Key Facts About Selank Research Peptide
| Property | Value |
|---|---|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Molecular weight | ~751.87 g/mol |
| Molecular formula | C33H57N9O9 |
| CAS number | 129954-34-3 |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) |
| Development origin | Russian Academy of Sciences / Zakusov Institute |
| Primary research domains | Anxiety models, serotonin, GABA-A, BDNF, neuroimmune |
| Key documented mechanism | GABA-A receptor benzodiazepine site (positive allosteric modulator) |
| Recommended storage (lyophilized) | -20°C short-term, -80°C long-term |
| Minimum research-grade purity | Greater than 98% HPLC |
| Regulatory status (US) | Research use only; not FDA-approved for human or veterinary use |
Supporting Articles in This Cluster
This pillar page is supported by ten deep-dive articles covering each aspect of Selank research in detail:
- History and Development of Selank Research Peptide: From Tuftsin Analog to Modern Lab Research Tool
- Molecular Structure and Sequence of Selank Research Peptide: Key Chemical Properties for Lab Scientists
- Preclinical Research Findings on Selank Research Peptide in Animal Models
- Synthesis and Manufacturing of High-Purity Selank Research Peptide for Laboratory Use
- Selank Research Peptide vs Semax Research Peptide: Key Differences for Neuroscience Lab Studies
- Best Practices for Storage, Stability, and Reconstitution of Selank Research Peptide in the Lab
- Selank Research Peptide Nasal Spray Formulations: Applications in Controlled Research Settings
- Mechanisms of Action of Selank Research Peptide in Neuroscience and Gene Expression Studies
- Quality Control and Purity Testing Standards for Selank Research Peptides
- How to Buy High-Purity Selank Research Peptide Online: A Guide for Research Laboratories
Frequently Asked Questions About Selank Research Peptide
Q: What is Selank research peptide?
A: Selank is a synthetic heptapeptide research compound with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed as a stable analog of the naturally occurring peptide tuftsin at the Russian Academy of Sciences. In preclinical animal model research, it has been studied for effects on anxiety-related behavior, serotonin metabolism, BDNF expression, and GABA-A receptor interactions.
Q: What is the molecular weight and sequence of Selank?
A: Selank has a molecular weight of approximately 751.87 g/mol and the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its molecular formula is C33H57N9O9.
Q: Is Selank approved for human use?
A: No. Selank has not been approved by the FDA or any equivalent regulatory authority for human or veterinary use. It is available in the United States strictly for licensed laboratory and preclinical research purposes.
Q: What has preclinical research shown about Selank?
A: Animal model studies have documented anxiolytic-like behavioral effects (without sedation), altered serotonin turnover in hippocampal and frontal cortex tissue, BDNF mRNA upregulation in hippocampal tissue, interaction with the GABA-A receptor benzodiazepine site, and broad gene expression changes in neural tissue. These are preclinical findings in animal models and do not constitute clinical evidence.
Q: What is Selank's mechanism of action?
A: The most precisely documented mechanism is positive allosteric modulation of the GABA-A receptor at the benzodiazepine binding site. Additional proposed mechanisms include inhibition of enkephalin-degrading enzymes, serotonin system modulation, and BDNF upregulation. The full mechanistic profile is not yet completely characterized.
Q: How is Selank different from Semax?
A: Both are heptapeptides with the Pro-Gly-Pro C-terminal motif, but their N-terminal sequences and research profiles differ significantly. Selank is derived from tuftsin and has the stronger preclinical literature in anxiety and neuroimmune models. Semax is derived from ACTH(4-7) and has the stronger literature in cognitive, memory, and neuroprotection models.
Q: How should Selank research peptide be stored?
A: Lyophilized Selank should be stored at -20°C (short-term) or -80°C (long-term), in sealed vials away from moisture and light. Reconstituted solutions should be aliquoted into single-use volumes and stored at -20°C for up to 30 days. Repeated freeze-thaw cycles should be avoided.
Q: What purity should research-grade Selank be?
A: Research-grade Selank should have HPLC purity greater than 98%, confirmed by mass spectrometry identity verification. A complete COA should also include net peptide content and residual solvent data.
References
- Seredenin SB, Voronina TA, Gudasheva TA, et al. "Anxiolytic activity of the novel peptide Selank in experimental models of anxiety." Eksperimental'naia i Klinicheskaia Farmakologiia. 1998.
- Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. "A new generation of drugs: synthetic peptides based on natural regulatory peptides." Neuroscience and Medicine. 2013;4:223-252.
- Grigor'ev VV, Ivanova TA, Kubatiev AA, Serkov IV, Gudasheva TA, Seredenin SB. "Mechanism of effects of the peptide Selank on the GABA(A) receptor complex." Doklady Biological Sciences. 2006;411:441-3.
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38-48.
- Uchakina ON, Uchakin PN, Miasoedov NF, et al. "Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(5):71-5.
- Narkevich VB, Kudrin VS, Klodt PM, et al. "Effects of the novel peptide anxiolytic Selank on monoamine metabolism in rats with different levels of anxiety." Eksperimental'naia i Klinicheskaia Farmakologiia. 2008;71(4):6-10.
- Najjar VA. "Tuftsin, a natural activator of phagocyte cells: an overview." Annals of the New York Academy of Sciences. 1983;419:1-11.
- Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskiy AA, Myasoedov NF. "Behavioral effects of Selank and its structural analogs in white rats and mice." Eksperimental'naia i Klinicheskaia Farmakologiia. 1999;62(3):8-12.
Author: Palmetto Peptides Research Team
This guide is for licensed research professionals only. Selank is not approved for human or veterinary use. View our Selank research peptide product page for current lot documentation, COA, and ordering information. Browse related research peptides including Semax, CJC-1295, Ipamorelin, and our full research peptide catalog.